Xariban 20 Tablet contains Rivaroxaban 20 mg, an oral anticoagulant classified as a direct Factor Xa inhibitor. It is indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Rivaroxaban selectively blocks the active site of Factor Xa, thereby inhibiting both free and clot-bound Factor Xa, which results in decreased thrombin generation and thrombus development. Xariban 20 offers a predictable anticoagulant effect with rapid onset of action and does not require routine coagulation monitoring, enhancing patient compliance. The tablet is administered orally, typically once daily, with or without food, depending on the indication. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in individuals with active pathological bleeding or significant hypersensitivity to the drug. Potential adverse effects include bleeding complications, which necessitate careful assessment of bleeding risk prior to initiation. Xariban 20 should be used under strict medical supervision, with appropriate dose adjustments or discontinuation in cases of surgery, trauma, or concomitant use of other anticoagulants or antiplatelet agents. This medication plays a critical role in the management of thromboembolic diseases, improving patient outcomes through effective anticoagulation.